Table 4.

Adverse events

Adverse event	Grade	Whole sample (n = 34)		*1/*1 (n = 20)		*1/*28 (n = 12)		*28/*28 (n = 2)
		n	%	n	%	n	%	n	%
Non-hematologic events
Nausea/vomiting	1–2	18	52.9	8	40	9	75	1	50
	3–4	10	29.4	7	35	3	25	0	0
Gastro-intestinal event	1–2	25	73.5	16	80	8	66.7	1	50
	3–4	5	14.7	2	10	2	16.7	1	50
Ear-nose-throat event	1–2	19	55.9	13	65	5	41.7	1	50
	3–4	4	11.8	2	10	1	8.3	1	50
Anorexia	1–2	20	58.8	10	50	9	75	1	50
	3–4	4	11.8	4	20	0	0	0	0
Asthenia	1–2	28	82.4	15	75	11	91.7	2	100
	3–4	5	14.7	4	20	1	8.3	0	0
Dermatological event	1–2	16	47.1	9	45	5	41.7	2	100
	3–4	1	2.9	0	0	1	8.3	0	0
Pain	1–2	9	26.5	5	25	3	25	1	50
Dyspnea	1–2	1	2.9	1	5	0	0	0	0
	3–4	1	2.9	1	5	0	0	0	0
Alopecia	1–2	4	11.8	2	10	2	16.7	0	0
Infection	1–2	9	26.5	3	15	6	50	0	0
	3–4	4	11.8	1	5	2	16.7	1	50
Neurological event	1–2	5	14.7	3	15	1	8.3	1	50
Hematologic events
Thrombocytopenia	1–2	8	23.5	5	25	2	16.7	1	50
Anemia	1–2	24	70.6	13	65	9	75	2	100
	3–4	1	2.9	1	5	0	0	0	0
Hypokalemia	1–2	4	11.8	1	5	3	25	0	0
	3–4	1	2.9	1	5	0	0	0	0
Leukopenia	1–2	25	73.5	15	75	8	66.7	2	100
	3–4	2	5.9	0	0	2	16.7	0	0
Lymphopenia	1–2	4	11.8	2	10	2	16.7	0	0
	3–4	4	11.8	2	10	2	16.7	0	0
Neutropenia	1–2	8	23.5	5	25	3	25	0	0
	3–4	15	44.1	10	50	4	33.3	1	50
Febrile neutropenia	3–4	3	8.8	1	5	2	16.7	0	0